ATE412778T1 - Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen - Google Patents

Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen

Info

Publication number
ATE412778T1
ATE412778T1 AT03730032T AT03730032T ATE412778T1 AT E412778 T1 ATE412778 T1 AT E412778T1 AT 03730032 T AT03730032 T AT 03730032T AT 03730032 T AT03730032 T AT 03730032T AT E412778 T1 ATE412778 T1 AT E412778T1
Authority
AT
Austria
Prior art keywords
obesity
gene
diagnosis
prevention
treatment
Prior art date
Application number
AT03730032T
Other languages
English (en)
Inventor
Peter Brooks
Elke Roschmann
Anne Philippi
Joerg Hager
Original Assignee
Integragen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02291201A external-priority patent/EP1362926A1/de
Priority claimed from EP20020292392 external-priority patent/EP1403380A1/de
Application filed by Integragen Sa filed Critical Integragen Sa
Application granted granted Critical
Publication of ATE412778T1 publication Critical patent/ATE412778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03730032T 2002-05-15 2003-05-14 Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen ATE412778T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02291201A EP1362926A1 (de) 2002-05-15 2002-05-15 Humanes fettleibigkeit Suszeptibilitätsgen und deren Verwendungen
EP20020292392 EP1403380A1 (de) 2002-09-27 2002-09-27 Humanes fettleibigkeit Suszeptibilitätsgen und deren Verwendungen

Publications (1)

Publication Number Publication Date
ATE412778T1 true ATE412778T1 (de) 2008-11-15

Family

ID=29551340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730032T ATE412778T1 (de) 2002-05-15 2003-05-14 Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen

Country Status (9)

Country Link
US (2) US20050123923A1 (de)
EP (3) EP1995331A1 (de)
AT (1) ATE412778T1 (de)
AU (1) AU2003240640B2 (de)
CA (1) CA2484176A1 (de)
DE (1) DE60324414D1 (de)
DK (1) DK1504125T3 (de)
ES (1) ES2314206T3 (de)
WO (1) WO2003097683A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829281B2 (en) 2004-09-17 2010-11-09 Children's Medical Center Corporation Compositions and methods for obesity screening using polymorphisms in NPY2R
EP1815027A1 (de) * 2004-11-22 2007-08-08 Integragen Für kaliumionenkanäle kodierendes humanes adipositas-suszeptibilitätsgen und dessen verwendung
JP2008536474A (ja) * 2004-12-09 2008-09-11 パーレジェン・サイエンシズ・インク． メタボリックシンドローム、肥満及びインスリン抵抗性のマーカー
EP4686763A1 (de) 2024-07-31 2026-02-04 Institut National de la Recherche pour l'Agriculture, l'Alimentation et l'Environnement Gensignaturen zur vorhersage der veranlagung zu fettleibigkeit

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
JPH10508486A (ja) * 1994-11-07 1998-08-25 メルク エンド カンパニー インコーポレーテッド 修飾神経ペプチドｙレセプター
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2000030674A1 (en) * 1998-11-26 2000-06-02 Ferring Bv Neuropeptide y y4 agents in the treatment of reproductive disorders
WO2001018250A2 (en) * 1999-09-10 2001-03-15 Whitehead Institute For Biomedical Research Single nucleotide polymorphisms in genes

Also Published As

Publication number Publication date
CA2484176A1 (en) 2003-11-27
DK1504125T3 (da) 2009-02-09
EP1995331A1 (de) 2008-11-26
US20050123923A1 (en) 2005-06-09
US20070154935A1 (en) 2007-07-05
EP1504125A2 (de) 2005-02-09
AU2003240640A1 (en) 2003-12-02
DE60324414D1 (de) 2008-12-11
WO2003097683A3 (en) 2004-04-01
WO2003097683A2 (en) 2003-11-27
ES2314206T3 (es) 2009-03-16
AU2003240640B2 (en) 2009-10-22
EP1997913A1 (de) 2008-12-03
EP1504125B1 (de) 2008-10-29

Similar Documents

Publication Publication Date Title
Tremblay et al. Role of genomics on the path to personalized medicine
Apostolova et al. Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis
Hunter et al. A genome-wide association study of a sustained pattern of antidepressant response
Fernandez et al. Familial dyskinesia and facial myokymia (FDFM): a novel movement disorder
WO2007025085A8 (en) Genemap of the human genes associated with crohn's disease
Chapman et al. Preliminary observations on APOE ϵ4 allele and progression of disability in multiple sclerosis
DE60324414D1 (de) Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen
WO2001081634A3 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
Lanza et al. A Customized Next‐Generation Sequencing‐Based Panel to Identify Novel Genetic Variants in Dementing Disorders: A Pilot Study
NO20021147D0 (no) Polymorfismer i det humane hPXR-genet og deres anvendelse i diagnostiske og terapeutiske applikasjoner
WO2005021787A3 (en) Human obesity susceptibility gene and uses thereof
IL179744A0 (en) Human obesity susceptibility gene encoding a potassium voltage-gated channel and uses thereof
AU7317400A (en) Transporter genes oatp-b, c, d and e
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
DE602005013080D1 (de) Für prkcb1 kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
Botis et al. Cognitive function in female patients with schizophrenia and metabolic syndrome
Nicol The variation of response to pharmacotherapy: Pharmacogenetics-a new perspective to'the right drug for the right person'
WO2005090600A3 (en) Human obesity susceptibility genes encoding peptide hormones and uses thereof
WO1999045112A3 (en) Chromosome 11-linked coronary heart disease susceptibility gene chd1
Marahatta et al. Genetic variants that influence fetal hemoglobin expression from hydroxyurea treatment
Wolthers et al. Common genetic variants in trypsin regulating genes are associated with asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte Di Legno Toxicity Working Group Study
WO2003102141A3 (en) Identification of a gene causing the most common form of bardet-biedl syndrome and uses thereof
Crivellaro et al. 5PSQ-091 Precision medicine: pharmacogenetic profiling and therapeutic drug monitoring as an integrated approach to breast cancer treatment
Skaare-Fatland et al. 5PSQ-092 Physical health assessment in patients with psychotic disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties